PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Dihydroxytryptamines”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,261 records · Page 70Linked to original sources

Involvement of brain monoamines in the delta-9-tetrahydrocannabinol-induced reduction of hippocampal choline uptake.

The role of monoamines in the transsynaptic reduction of neuronal activity produced by delta 9-tetrahydrocannabinol (delta 9-THC) in the septal-hippocampal cholinergic pathway has been investigated. Serotonergic afferents were chemically lesioned by unilateral infusion of 5,7-dihydroxytryptamine. Noradrenergic and dopaminergic inputs were selectively deleted by unilateral infusion of 6-hydroxydopamine into appropriate anatomic sites. Although removal of serotonergic and noradrenergic input did not alter hippocampal choline uptake relative to the contralateral control side, dopaminergic input reduction produced a significant elevation. After administration of delta 9-THC (20 mg/kg), reduction of choline uptake into lesioned hippocampi was not significantly different from that for the controls. These results indicate that monoaminergic afferents do not play a major role in the effect of delta 9-THC on cholinergic activity in the rat hippocampus.

5,7-Dihydroxytryptamine↗

Cardiovascular functions of central noradrenergic and serotonergic neurons in conscious rabbits. Their contributions to the central actions of clonidine.

Synaptic release of transmitter from central noradrenergic (NA) and serotonergic (5HT) neurons was studied in intact and pontine decerebrate unanesthetized rabbits, following intracisternal injections of the selective neurotoxic drugs 6-hydroxydopamine (6-OHDA) and 5,6-dihydroxytryptamine (5,6-DHT). The NA and 5HT neurons both raise blood pressure through a suprapontine pathway, with 5HT neurons in series with NA neurons. Descending bulbospinal fibers have antagonistic effects on blood pressure, with NA release lowering blood pressure and 5HT release increasing it. The two transmitters also have antagonistic effects on the cardiac vagus, with NA neurons increasing vagal activity and 5HT neurons inhibiting it. Our results suggest that both NA and 5HT neurons contribute to the cardiovascular effects of clonidine. The actions of clonidine on blood pressure and heart rate mimic the effects of NA and are opposite those of 5HT released at synaptic sites in the bulb and spinal cord.

5,6-Dihydroxytryptamine↗

An evaluation of the mechanism by which serotonergic activation depresses respiration.

The present investigation attempted to determine if the previously reported depression of respiration by serotonergic agonists was a result of peripheral or central nervous system drug effects. Systemic administration of 5-hydroxytryptophan (5-HTP) to pargyline-treated animals and 5-methoxy-N,N-di-methyltryptophan (5-MDMT) probably depress respiration secondary to central penetration of these drugs, since: 1) adult rats with biochemical evidence of partial destruction of central serotonergic neurons after neonatal intracisternal 5,7-dihydroxytryptamine were supersensitive to the respiratory depressing effect of 5-HTP and 5-MDMT; 2) the ventilatory effect of the serotonergic agonists was not reduced by surgical deafferentiation induced by bilateral transection of the glossopharyngeal nerves; 3) after sectioning of the vagus nerve, the absolute change produced by serotonergic agonists was less; however, the relative change was unaltered; and 4) inhibition of peripheral aromatic amino acid decarboxylase by RO-4-4602 significantly blunted the respiratory depressant activity of 5-HTP observed at 15 min but not that present 30 min after 5-HTP. The present fidings thus suggest that the cenvel by the activity of central serotonergic neurons.

5,7-Dihydroxytryptamine↗

Serotonin nerve endings and regulation of pupillary diameter.

On the basis of the effects caused by 5-6-dihydroxytryptamine (5-6-DHT) on the serotonin nerve endings (chronic degeneration with depletion of the mediator), the eventual existence of serotoninergic fiber regulating pupillary diameter (PD) and intraocular pressure (IOP) was studied from a functional point of view. For the miotic effect found after administration of 5-6-DHT in rabbit, not accompanied by any change in the IOP, the hypothesis of a coparticipation of the serotoninergic fibers in the regulation of the PD is proposed, thus sustaining the concept that both PD and IOP respond to mechanisms of autonomous control. A phenomenon of receptorial supersensitivity to serotonin after the lesion of the nerve endings, dependent on 5-6-DHT, was also encountered.

5,6-Dihydroxytryptamine↗

Alteration of aminophylline-induced respiratory stimulation by perturbation of biogenic amine systems.

Aminophylline-induced stimulation of respiration in halothane-anesthetized rats was abolished in rats given 6-hydroxydopamine and desmethylimipramine neonatally to selectively destroy central nervous system dopamine nerve terminals. The respiratory stimulation was also prevented by prior administration of dopamine receptor antagonists haloperidol and cisflupenthixol. The combination of apomorphine and aminophylline produced an additive stimulatory effect on respiration to values greater than those observed with either drug alone. Animals which received pargyline and 5,7-dihydroxytryptamine neonatally to selectively destroy central nervous system serotonin nerve terminals appeared to be more sensitive to the stimulatory effects of aminophylline on respiration when tested as adults. The depressant effect of 5-methoxy-N, N-dimethyl-tryptamine on respiration was slightly enhanced in the presence of aminophylline. These data suggest that the respiratory response to aminophylline is the summation of the effects of this drug on central nervous system dopamine on serotonin neuronal systems.

5,7-Dihydroxytryptamine↗

Modification of environmentally cued tolerance to ethanol in mice.

Tolerance to the hypnotic and hypothermic effects of ethanol in mice develops with multiple injections. The tolerance to both of these effects of ethanol can be reduced by testing the animals in a novel environment, suggesting that the tolerance may be learned. Tolerance to the hypothermic effect of ethanol develops more rapidly than tolerance to the hypnotic effect. Disruption of the brain catecholamine systems, with either 6-hydroxydopamine or alpha-methyl-p-tyrosine slows the rate of development of tolerance to the hypnotic effect of ethanol. Intraventricular injection of the serotonergic neurotoxin 5,7-dihydroxytryptamine, increases initial sensitivity to ethanol-induced narcosis and facilitates the development of tolerance to the hypnotic effects of ethanol. Tolerance to the hypothermic effect of ethanol in a familiar environment is unaffected by either of the neurotoxins or by alpha-methyl-p-tyrosine. However, initial sensitivity to the temperature-lowering effect of ethanol is increased by 6-hydroxydopamine and decreased by alpha-methyl-p-tyrosine administration. Learning may be an important factor in development of tolerance to ethanol under some conditions and tolerance produced under these conditions can be modified by disruption of central catecholamine systems.

5,7-Dihydroxytryptamine↗

Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity.

The potentiation of the stimulatory response to L-dihydroxyphenylalanine (L-dopa) in 6-hydroxydopamine-treated rats given a peripheral decarboxylase inhibitor occurred only after treatments that destroyed dopamine-containing fibers, Destruction of serotonin- or norepinephrine-containing fibers did not potentiate the action of L-dopa. Furthermore, other data indicated thatL-dopa-induced activity could not be attributed to release of serotonin or to the formation of norepinephrine. That the L-dopa must be converted to catecholamines was demonstrated by antagonism of the activity responses to L-dopa with inhibition of decarboxylases in brain. After destruction of serotonin-containing fibers with 5,7-dihydroxytryptamine, L-dopa-induced activity in 6-hydroxydopamine-treated rats was significantly reduced, as was the accumulation of dopamine formed from L-dopa. These latter data provide direct evidence that serotonergic fibers contribute to the accumulation of dopamine in brain after L-dopa administration to 6-hydroxydopamine-treated rats.

5,7-Dihydroxytryptamine↗

[Serotoninergic nerve fibers in the area of the substantia grisea and the ependyma of the cerebral aqueduct].

An electron microscopic study of the midbrain gravy with the help of degeneration caused by serotonin-like neurotoxin 5,7-dihydroxytryptamine has shown that serotonergic terminals are responsible for the innervation of dendrites, neuron bodies and ependyma cells of the cerebral aqueduct. The detection of light, dark with prevailing fine transparent or large granular synaptic vesicles as well as vacuole degeneration evidences of the existence of several sources of serotonergic innervation of the central gray substance. Continuous damage of perivascular astrocytes of the central gray by neurotoxin allows a suggestion to be made that they are also the object of serotonergic innervation. Immunomorphological data on the presence of serotoninergic neurons in the cerebral gray are confirmed.

5,7-Dihydroxytryptamine↗

Endogenous serotonin stimulates striatal dopamine release in conscious rats.

Serotonin (5-HT) and dopamine (DA) are established neurotransmitters in the brain. This study examined whether, in conscious, free-moving rats, increased concentrations of endogenous 5-HT in extracellular fluid of the corpus striatum affect local release of endogenous DA. Administration of the 5-HT reuptake blocker alaproclate via a microdialysis probe increased striatal dialysate levels of DA and its metabolites dihydroxyphenylacetic acid and homovanillic acid as well as levels of 5-HT and the 5-HT metabolite 5-hydroxyindoleacetic acid. Whereas DA reuptake blockade with GBR-12909 did not prevent these effects of alaproclate, serotonergic ablation by i.c.v. administration of 5,7-dihydroxytryptamine markedly decreased basal levels of 5-HT and 5-hydroxyindoleacetic acid and abolished the effects of alaproclate on dialysate levels of DA, 5-HT and their metabolites. The results are consistent with a stimulatory action of endogenous 5-HT on striatal DA release in conscious animals.

5,7-Dihydroxytryptamine↗

p,p'-DDT myoclonic/epileptic model: serotonin receptor binding and behavioral studies in the rat.

An abnormality of serotonergic neurotransmission has been hypothesized in p,p'-DDT intoxication to explain myoclonus and the antimyoclonic properties of 5-hydroxytryptophan (5-HTP). To study the role of serotonin (5-HT) receptors in myoclonus induced by p,p'-DDT in the rat, we performed time-course and dose-response studies of the effects of p,p'-DDT on behavior and regional 5-HT1 and 5-HT2 binding sites. At a time when low dose (80 mg/kg) p,p'-DDT elicited stimulus-sensitive and spontaneous myoclonus, there were no significant changes in Bmax or Kd of 5-HT1A, 5-HT1B, 5-HT1C sites in cortex, striatum, brainstem or spinal cord, agonist- or antagonist-labelled 5-HT2 sites in cortex, or 5-HT uptake sites. High dose p,p'-DDT (1000 but not 500 mg/kg), which also induced convulsions, only slightly increased 5-HT1 (unsubtyped) binding sites in cortex but not in brainstem or spinal cord and had no effect on antagonist-labelled 5-HT2 sites. In naive frontal cortex in vitro, 1 microM p,p'-DDT displaced neither [3H]5-HT or [3H]ketanserin specific binding. Lesions of central indoleamine neurons made with 5,7-dihydroxytryptamine significantly prolonged the latency and attenuated the severity of p,p'-DDT behavioral abnormalities, increasing the dose of p,p'-DDT which induced myoclonus (MD50) or convulsions (CD50) in 50 percent of the rats. This is the first report of 5,7-DHT-induced attenuation in the p,p'-DDT myoclonic model.

5,7-Dihydroxytryptamine↗

Effect of serotonin depletion on vibrissa-related patterns of thalamic afferents in the rat's somatosensory cortex.

To investigate the role of 5-HT in the development of the somatosensory cortex, this amine was depleted in newborn (P-0) rats with a single subcutaneous injection of the toxin 5,7-dihydroxytryptamine (5,7-DHT) and thalamocortical organization was assayed by application of the carbocyanine dye Di-I to the thalamocortical radiations or ventrobasal thalamus, or by staining cortical sections for AChE or cytochrome oxidase (CO). High-performance liquid chromatographic analysis of cortices from animals killed on P-6 or P > 60 demonstrated that 5,7-DHT treatment resulted in 85.04 +/- 12.6% and 72.5 +/- 1.5% reductions in cortical 5-HT, respectively. Alternate cortices from the brains of animals killed on P-6 processed for 5-HT immunoreactivity demonstrated a complete absence of the vibrissa-related pattern of immunoreactivity and only a small number of coarse immunoreactive axons. The 85% depletion of 5-HT did not alter the somatotopic organization of thalamocortical afferents in animals killed on P-6 or P > 60, but it did cause 30.5 +/- 7.3% and 19.1 +/- 3.7% reductions in the cross-sectional areas of the patches of thalamocortical afferents corresponding to the long mystacial vibrissae (p < 0.05). These reductions were not associated with significant reductions in either brain or cortical weight or with decreases in the dimensions of the thalamic representation of the vibrissa follicles. These results indicate that 5-HT plays a significant role in the development of the thalamic innervation of the primary somatosensory cortex.

5,7-Dihydroxytryptamine↗

High and low affinity 5-HT2 and 5-HT1C binding sites: responses to neonatal 5,7-DHT lesions in rat brain.

5-HT receptor denervation supersensitivity has been proposed to explain behavioural supersensitivity to L-5-HTP in rats with 5,7-dihydroxytryptamine (5,7-DHT) lesions. No upregulation of 5-HT2 binding sites was found despite supersensitivity to putative 5-HT2,1C drugs. To test the hypothesis that the 5-HT1C properties of these drugs are involved instead, dose-response and time-course studies of 5-HT1C and 5-HT2 receptors were performed using several different radioligands in rat brain after making neonatal 5,7-DHT lesions by intraperitoneal injection. 5-HT1C sites labelled with [3H]-mesulergine showed a distinct regional distribution: brainstem > diencephalon > cortex > hippocampus > cerebellum, constituting 65, 70, 31, 70, and 73% of total sites labelled by [3H]-mesulergine in the absence of 20 nM spiperone to block 5-HT2 sites, respectively. 5,7-DHT lesions did not significantly alter BMAX, KD, or nH of [3H]-mesulergine-labelled 5-HT1C sites in cortex or other regions but did reduce the density of cortical [3H]-paroxetine sites (-55%). Cortical 5-HT1C sites labelled by [3H]-5-HT or [3H]-mianserin, and cortical 5-HT2 sites labelled by [3H]-DOB or [3H]-ketanserin, were also unaffected. These data suggest that although denervation supersensitivity of 5-HT1C or 5-HT2 receptors may occur at the level of the receptor transducer-effector, there is no evidence it occurs at the receptor recognition site.

5,7-Dihydroxytryptamine↗

5HT2 receptors mediate the effects of stress on the activity of periventricular hypophysial dopaminergic neurons and the secretion of alpha-melanocyte-stimulating hormone.

The roles of 5-hydroxytryptaminergic (5HT) neurons and receptor subtypes in mediating the effects of stress on the activity of periventricular hypophysial dopaminergic (PHDA) neurons and the secretion of alpha-melanocyte-stimulating hormone (alpha MSH) were examined in female rats. Periventricular hypophysial dopaminergic neuronal activity was estimated by measuring concentrations of 3,4-dihydroxyphenylacetic acid in the intermediate lobe of the pituitary. Brief exposure to diethylether followed by 30 min of supine restraint decreased intermediate lobe 3,4-dihydroxyphenylacetic acid concentrations and increased plasma concentrations of alpha MSH. These stress-induced effects were not observed in animals in which 5HT neurons had been previously destroyed by 5,7-dihydroxytryptamine or inhibited by the administration of the 5HT1A receptor agonist 8-hydroxy-2-(di-n-propyl-amino)-tetralin. Pretreatment of rats with the 5HT2 receptor antagonist MDL-11,939 blocked the inhibitory effects of stress on intermediate lobe 3,4-dihydroxyphenylacetic acid concentrations and the corresponding increase in plasma alpha MSH concentrations, whereas the 5HT3 receptor antagonist ondansetron was without effect. These results reveal that 5HT neurons, acting via 5HT2 receptors, mediate the inhibitory effects of stress on periventricular hypophysial dopaminergic neurons and the consequent increase in secretion of alpha MSH.

3,4-Dihydroxyphenylacetic Acid↗

5-HT1A receptors and the tail-flick response. IV. Spinally localized 5-HT1A receptors postsynaptic to serotoninergic neurones mediate spontaneous tail-flicks in the rat.

The present study examined the location of the serotonin (5-HT)1A receptors mediating the induction of spontaneous tail-flicks (STFs) in the rat. Serotoninergic neurones were lesioned by i.c.v. administration of 5,7-dihydroxytryptamine, which depleted levels of 5-HT in the spinal cord and other CNS tissues by > 90% without affecting those of noradrenaline and dopamine. In lesioned rats, the ability of the 5-HT releasers, para-chloroamphetamine and methylenedioxymethamphetamine, to elicit STFs was abolished. In contrast, the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)- tetralin (8-OH-DPAT), continued to evoke STFs. In fact, its effect was significantly enhanced in lesioned as compared with sham animals. In (nonlesioned) rats with catheters chronically implanted at the lumbar spinal level, intrathecal 8-OH-DPAT dose-dependently evoked STFs. The action of 8-OH-DPAT was extremely rapid, being maximal within 1 min of injection. Whereas the 5-HT1B/C agonist, TFMPP, the 5-HT1C/2 agonist, DOI, and the 5-HT3 agonist, m-chlorophenylbiguanide, failed to elicit STFs, the action of 8-OH-DPAT was mimicked by several other 5-HT1A agonists: S 14671, 5-MeODMT and lisuride. These also showed a time-course with a rapid onset. Further, the highly hydrophilic 5-HT1A agonist, 5-carboxyamidotryptamine, which fails to pass the blood-brain barrier, likewise dose-dependently elicited STFs upon direct lumbar administration. In contrast, administered onto the cervical spinal cord, it was completely ineffective. Systemic administration of the 5-HT1A antagonists, BMY 7378 or (-)-alprenolol, but not of the 5-HT1C/2 antagonist, ritanserin, nor of the 5-HT3 antagonist, ondansetron, blocked STFs elicited by lumbar administration of 8-OH-DPAT. Conversely, lumbar (but not cervical) administration of BMY 7378 and (-)-alprenolol dose-dependently blocked the action of systemic 8-OH-DPAT. These data demonstrate that STFs in the rat are mediated by 5-HT1A receptors postsynaptic to 5-HT neurones and localized in the lumbar spinal cord. Further, they support the concept of a relationship between STFs and mechanisms of primary sensory (nociceptive) processing.

5,7-Dihydroxytryptamine↗

Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists.

In this study, we examined the localization of the 5-hydroxytryptamine (5-HT)1A receptors mediating hypothermia in the rat, evaluated the pharmacological specificity of this response and examined the influence of a series of novel 5-HT1A receptor ligands upon core temperature. Administered s.c., 8-hydroxy-(2-di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), an agonist at both pre- and postsynaptic 5-HT1A receptors, elicited pronounced hypothermia. In contrast, BMY 7378, which shows low efficacy at postsynaptic 5-HT1A receptors but high efficacy at presynaptic 5-HT1A receptors, elicited only mild hypothermia. Similarly, 8-OH-DPAT was more efficacious than BMY 7378 in eliciting corticosterone secretion, a response mediated by postsynaptic 5-HT1A receptors, whereas BMY 7378 was as efficacious as 8-OH-DPAT in inhibiting striatal accumulation of 5-hydroxytryptophan, a response mediated by presynaptic 5-HT1A receptors. These data suggest, by analogy, that postsynaptic 5-HT1A receptors mediate hypothermia, an interpretation supported by the observation that destruction of central 5-HT neurons with 5,7-dihydroxytryptamine failed to reduce 8-OH-DPAT-induced hypothermia (DIH). Agonists at 5-HT1B, 5-HT1C, 5-HT2 and/or 5-HT3 receptors did not elicit hypothermia, and drugs releasing 5-HT elicited hyperthermia. In contrast, DIH was fully mimicked by the novel 5-HT1A receptors agonists, eltoprazine, WY 48,723, MDL 72832, tandospirone, S 14671, S 14506 and WY 50,324, whereas the novel partial agonist, zalospirone, was less efficacious. DIH was blocked by (-)-alprenolol, (+/-)-pindolol and the novel beta-blocker, (-)-tertatolol, which also has high affinity for 5-HT1A receptors; in distinction, betaxolol and ICI 118,551, antagonists at beta-1 and beta-2 adrenoceptors, respectively, were inactive. Spiperone, NAN-190 and BMY 7378 also inhibited DIH whereas ritanserin, SCH 39166, raclopride and prazosin, antagonists at 5-HT2 receptors, D1 and D2 dopamine receptors and alpha-1 adrenoceptors, respectively, were inactive. The novel 5-HT1A antagonists, WAY 100,135, MDL 73005 EF and (very potently) SDZ 216-525 all blocked DIH. Potency for induction of hypothermia and inhibition of DIH correlated well with affinity for 5-HT1A binding sites. In conclusion, hypothermia is a highly specific and sensitive response to activation of postsynaptic 5-HT1A receptors. Furthermore, DIH is inhibited by their selective blockade. At postsynaptic 5-HT1A receptors mediating hypothermia, eltoprazine, WY 48,723, MDL 72832 and tandospirone are agonists, zalospirone is a partial agonist and (-)-tertatolol, WAY 100,135, MDL 73005 EF and SDZ 216-525 are antagonists.

5,7-Dihydroxytryptamine↗

Short-term effects of 2,4,5-trihydroxyamphetamine, 2,4,5-trihydroxymethamphetamine and 3,4-dihydroxymethamphetamine on central tryptophan hydroxylase activity.

In previous studies, we have reported the long-term effects of several metabolites of 3,4-methylenedioxymethamphetamine (MDMA) on tryptophan hydroxylase (TPH) activity. In this study, the short-term effects of three metabolites of MDMA. 2,4,5-trihydroxyamphetamine (THA), 2,4,5-trihydroxymethamphetamine (THM) and 3,4-dihydroxymethamphetamine, and the in vitro effect of THA on TPH activity are reported. After short-term treatment, hippocampal TPH activity was decreased to 8 and 54% of control in response to THA and THM, respectively, but was unaltered after 3,4-dihydroxymethamphetamine. Incubating TPH from THM-treated rats with dithiothreitol under nitrogen failed to reverse the decrease in enzyme activity induced by THM treatment. THA also decreased tyrosine hydroxylase activity to 75% of control, whereas the enzyme activity remained unaltered by THM. The structural analog of THA, 6-hydroxydopamine, failed to reproduce the effect of THA on TPH activity; however, 5,6-dihydroxytryptamine decreased hippocampal TPH activity to 18% of control. In the in vitro study, the hippocampus and the striatum were incubated in varying concentrations of THA. After a 1-h incubation at 37 degrees C, hippocampal TPH activity was decreased to 83, 71, 68, 47 and 3% of control after exposure to 0.001, 0.01, 0.1, 0.5 or 5.0 mM THA, respectively; striatal TPH activity was reduced to 98, 95, 70, 54 and 17% of control, respectively. Incubating the enzyme under reducing conditions failed to restore the enzyme activity to control levels.(ABSTRACT TRUNCATED AT 250 WORDS)

5,6-Dihydroxytryptamine↗

Neurotoxin-induced lesions to central serotonergic, noradrenergic and dopaminergic systems modify caffeine-induced antinociception in the formalin test and locomotor stimulation in rats.

Our study examined the effects of neurotoxin-induced lesions to central 5-hydroxytryptamine (5-HT), noradrenaline (NA) and dopamine (DA) systems on antinociception by caffeine in the formalin test and on locomotor stimulation by caffeine. Locomotor activity was determined simultaneously with responses to formalin, although in some studies, scores were derived in the absence of formalin. Rats were tested 10 to 12 days after toxin administration, and amine levels in brain regions and the spinal cord determined at the end of the experiment. Intracerebroventricular 5,7-dihydroxytryptamine (+/- desipramine) (which depleted central 5-HT systems) inhibited antinociception by caffeine but had no effect on locomotor stimulation. Intracerebroventricular 6-hydroxydopamine (which depleted NA in brain and spinal cord and DA in brain) augmented both antinociception and locomotor stimulation by caffeine. Both effects were due to NA depletion as they were mimicked by microinjection of 6-hydroxydopamine into the locus ceruleus that selectively depleted NA, not by intracerebroventricular 6-hydroxydopamine with desipramine that selectively depleted DA. In the absence of formalin, locus ceruleus lesions no longer had a significant effect on locomotor stimulation. Phentolamine, an alpha-adrenergic antagonist, inhibited caffeine-induced locomotor stimulation in the absence of formalin. These neurotoxin-induced lesions reveal an involvement of central 5-HT and NA (but not DA) systems in antinociception, and an involvement of central NA (but not 5-HT or DA) systems in locomotor stimulation. There appears to be an interrelationship between noxious stimulation and the expression of locomotor activity.

5,7-Dihydroxytryptamine↗